Insilico’s IPF candidate links, and tests, AI-led target and compound discovery

Developed in less than 18 months for $1.8 million, Insilico’s preclinical lung fibrosis candidate showcases the speed and cost advantages of marrying the AI company’s target and compound discovery platforms. The question is whether linking biological hypotheses based on big data with computer-generated chemical designs will increase the chances of success in the clinic.

On Wednesday,  Insilico Medicine Inc. said its Pandaomics and Chemistry 42 platforms had respectively identified an undisclosed target for idiopathic pulmonary fibrosis (IPF) and a lead candidate with disease-modifying effects, which is now in IND-enabling studies...